AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18350270 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox21 (79% helium) via a standard non-rebreathe reservoir mask
Number of subjects: 6
Study 18350270 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox via a tightly fitting cushioned facemask
Number of subjects: 6
Study 18350270 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal breathing of Heliox21
Number of subjects: 6
Study 16035709 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst TENS stimulation
Number of subjects: 18
Study 16035709 — intervention group
Group type: COMPARATOR
Intervention: No stimulus (Control)
Number of subjects: 18
Study 11895532 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage intervention
Number of subjects: 60
Study 11895532 — intervention group
Group type: COMPARATOR
Intervention: Control (no massage)
Number of subjects: 60
Study 10047626 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of lovastatin
Number of subjects: 30
Study 10047626 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of pravastatin
Number of subjects: 30
Study 10047626 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 30
Study 7744265 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT therapy
Number of subjects: 0
Study 7744265 — intervention group
Group type: COMPARATOR
Intervention: No AZT therapy
Number of subjects: 0
Study 2116690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (10 mg/kg) daily during donor-specific transfusion (DST)
Number of subjects: 80
Study 2116690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cyclosporine)
Number of subjects: 80
Study 2116690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (10 mg/kg) during DST
Number of subjects: 80
Study 6451351 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoProvera 25mg
Number of subjects: 4
Study 6451351 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoProvera 50mg
Number of subjects: 4
Study 6451351 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoProvera 100mg
Number of subjects: 4
Study 6451351 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoProvera 150mg
Number of subjects: 4
Study 6451351 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoProvera 100mg and 150mg
Number of subjects: 4
Study 6451351 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoProvera (all doses)
Number of subjects: 4
Study 31064089 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme Weather Events (EWE)
Number of subjects: 350
Study 31064089 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation Measures
Number of subjects: 350
Study 31064089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Spells
Number of subjects: 350
Study 28780595 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray (Group V)
Number of subjects: 90
Study 28780595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (Group L)
Number of subjects: 90
Study 28780595 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 90
Study 26202595 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) plus veliparib 20 mg
Number of subjects: 346
Study 26202595 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) plus veliparib 40 mg
Number of subjects: 346
Study 26202595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 23066973 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA904 (active treatment)
Number of subjects: 32
Study 23066973 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 32
Study 21287313 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal reinforcement, no-limited-hold condition
Number of subjects: 0
Study 21287313 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal reinforcement condition
Number of subjects: 0
Study 21287313 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of baseline training trials
Number of subjects: 0
Study 21287313 — intervention group
Group type: EXPERIMENTAL
Intervention: Response speed
Number of subjects: 0
Study 21287313 — intervention group
Group type: EXPERIMENTAL
Intervention: Response accuracy
Number of subjects: 0
Study 19626470 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy with ABCB1 polymorphism
Number of subjects: 48
Study 19626470 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid therapy without ABCB1 polymorphism (Control group)
Number of subjects: 48
Study 19626470 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 48
Study 17094818 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual problem-solving treatment
Number of subjects: 236
Study 17094818 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Number of subjects: 236
Study 17094818 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study 15593198 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mug/day teriparatide
Number of subjects: 444
Study 15593198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study 11348716 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (administered to hospitalized patients)
Number of subjects: 228
Study 11348716 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine (administered to ambulatory clinic patients)
Number of subjects: 228
Study 9562516 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing anti-TNF-alpha monoclonal antibodies
Number of subjects: 0
Study 9562516 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IL-10
Number of subjects: 0
Study 8102720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 11124
Study 2890670 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg
Number of subjects: 5
Study 2890670 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 30 mg
Number of subjects: 5
Study 2890670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital 150 mg
Number of subjects: 5
Study 2890670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30470764 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive individuals not on antiretroviral treatment (ART)
Number of subjects: 5059
Study 30470764 — intervention group
Group type: COMPARATOR
Intervention: HIV negative individuals
Number of subjects: 5059
Study 30470764 — intervention group
Group type: COMPARATOR
Intervention: Individuals on ART
Number of subjects: 5059
Study 29903135 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk supplemented with inulin (150 mg/100 g), vitamin D3 (2.0 μg/100 g), casein phosphopeptides (5.0 mg/100 mL), milk minerals (40 mg/100 g)
Number of subjects: 42
Study 29903135 — intervention group
Group type: COMPARATOR
Intervention: Low-lactose whole milk
Number of subjects: 42
Study 25558641 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration treatment
Number of subjects: 16
Study 25558641 — intervention group
Group type: COMPARATOR
Intervention: Control (no whole-body vibration)
Number of subjects: 16
Study 22218671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 592
Study 22218671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study 20837852 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune globulin intravenous, 10% caprylate‐chromatography purified (2 g/kg loading dose, 1 g/kg maintenance every 3 weeks)
Number of subjects: 117
Study 20837852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (loading dose and maintenance every 3 weeks)
Number of subjects: 117
Study 18793067 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS I intervention during infancy
Number of subjects: 0
Study 18793067 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS II intervention during toddler-preschool phase
Number of subjects: 0
Study 18793067 — intervention group
Group type: COMPARATOR
Intervention: Developmental Assessment Sessions condition
Number of subjects: 0
Study 18793067 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS I and PALS II interventions across both periods
Number of subjects: 0
Study 16324142 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE non-etch
Number of subjects: 29
Study 16324142 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE etch
Number of subjects: 29
Study 14569932 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-examination education program
Number of subjects: 123748
Study 14569932 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123748
Study 10425464 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.3 IU/kg per day s.c.) and IGF-I (80 microgram/kg per day s.c.)
Number of subjects: 24
Study 10425464 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.3 IU/kg per day s.c.)
Number of subjects: 24
Study 10425464 — intervention group
Group type: EXPERIMENTAL
Intervention: GH and IGF-I
Number of subjects: 24
Study 10425464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline s.c.)
Number of subjects: 24
Study 10425464 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone alone
Number of subjects: 24
Study 7491395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium 600 mg loading dose
Number of subjects: 16
Study 1822317 — intervention group
Group type: EXPERIMENTAL
Intervention: Aniracetam (Ro 13-5057)
Number of subjects: 109
Study 1822317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 7035480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prophylactic urea treatment (low doses)
Number of subjects: 79
Study 7035480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 79
Study 31887743 — intervention group
Group type: EXPERIMENTAL
Intervention: MIV‐711, 100 mg daily
Number of subjects: 244
Study 31887743 — intervention group
Group type: EXPERIMENTAL
Intervention: MIV‐711, 200 mg daily
Number of subjects: 244
Study 31887743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 31887743 — intervention group
Group type: EXPERIMENTAL
Intervention: MIV‐711 (both dosages)
Number of subjects: 244
Study 29944510 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% drops
Number of subjects: 60
Study 29944510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% ophthalmic drops
Number of subjects: 60
Study 29944510 — intervention group
Group type: COMPARATOR
Intervention: Control (no NSAID applied until the third day)
Number of subjects: 60
Study 27922719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate (TDF)
Number of subjects: 1147
Study 27922719 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF in combination with emtricitabine (FTC)
Number of subjects: 1147
Study 27922719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1147
Study 25613986 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar Auditory Sensory Training (FAST)
Number of subjects: 15
Study 25613986 — intervention group
Group type: COMPARATOR
Intervention: Placebo of silence
Number of subjects: 15
Study 24372182 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicines
Number of subjects: 400
Study 23136538 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose parecoxib (40mg at 30min before the end of surgery, at 8 and 20hr after surgery)
Number of subjects: 126
Study 23136538 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose parecoxib (40mg at 30min before the end of surgery)
Number of subjects: 126
Study 23136538 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline at the same three time points)
Number of subjects: 126
Study 23136538 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose parecoxib
Number of subjects: 126
Study 23136538 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 126
Study 19406258 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4157
Study 19406258 — intervention group
Group type: COMPARATOR
Intervention: Heparin + GPI
Number of subjects: 4157
Study 19406258 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 4157
Study 19406258 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 4157
Study 17388667 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma 25(OH)D levels and the less functional FokI ff genotype
Number of subjects: 14116
Study 17388667 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma 25(OH)D levels (above median)
Number of subjects: 14116
Study 17388667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 25(OH)D and 1,25(OH)D levels below the median
Number of subjects: 14116
Study 17388667 — intervention group
Group type: COMPARATOR
Intervention: Plasma 25(OH)D levels above the median with FokI FF or Ff genotype
Number of subjects: 14116
Study 15457579 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG (200 IU intramuscularly every 4 weeks from 28 weeks of gestation to delivery)
Number of subjects: 112
Study 15457579 — intervention group
Group type: COMPARATOR
Intervention: Control (no special treatment)
Number of subjects: 112
Study 11800450 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmation call made one working day before appointment
Number of subjects: 313
Study 11800450 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmation call made two working days before appointment
Number of subjects: 313
Study 11800450 — intervention group
Group type: COMPARATOR
Intervention: Control group (no confirmation call)
Number of subjects: 313
Study 11800450 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall confirmation calls (both groups)
Number of subjects: 313
Study 9547681 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE unit intervention
Number of subjects: 0
Study 9547681 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 8284765 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 0
Study 3338362 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo therapy prior to the meal
Number of subjects: 20
Study 3338362 — intervention group
Group type: COMPARATOR
Intervention: No placebo therapy prior to the meal
Number of subjects: 20
Study 4948415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral killed typhoid vaccine (3 tablets containing 100x10(9) killed Salmonella typhi)
Number of subjects: 13374
Study 4948415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 tablets)
Number of subjects: 13374
Study 31567041 — intervention group
Group type: COMPARATOR
Intervention: Cash incentive of 5 Nigerian naira (C5)
Number of subjects: 2482
Study 31567041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentive of 300 Nigerian naira (C300)
Number of subjects: 2482
Study 31567041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentive of 800 Nigerian naira (C800)
Number of subjects: 2482
Study 30595283 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 60 mg loading dose (group A)
Number of subjects: 332
Study 30595283 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg loading dose (group B)
Number of subjects: 332
Study 27387557 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia measured with the Tampa Scale of Kinesiophobia (TSK-11) at baseline and 12-month follow-up.
Number of subjects: 433
Study 27387557 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations of demographic, cognitive affective, and pain-related variables to kinesiophobia.
Number of subjects: 433
Study 24772585 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic SFC
Number of subjects: 51
Study 24772585 — intervention group
Group type: COMPARATOR
Intervention: Original SFC
Number of subjects: 51
Study 24772585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 51
Study 22865477 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte depletion (LD)
Number of subjects: 70
Study 22865477 — intervention group
Group type: COMPARATOR
Intervention: Standard arterial filters (Controls)
Number of subjects: 70
Study 20861205 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pump flow (20% more than the usual flow during hypothermia)
Number of subjects: 12
Study 20861205 — intervention group
Group type: COMPARATOR
Intervention: Normal flow
Number of subjects: 12
Study 18664040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental movement skills (FMS) proficiency
Number of subjects: 248
Study 18664040 — intervention group
Group type: COMPARATOR
Intervention: Weight status
Number of subjects: 248
Study 16846322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (8 churches)
Number of subjects: 755
Study 16846322 — intervention group
Group type: COMPARATOR
Intervention: Control (6 churches)
Number of subjects: 755
Study 12654359 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1-g single dose)
Number of subjects: 78
Study 12654359 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily for 10 days)
Number of subjects: 78
Study 10037363 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL) with 1,800 to 3,200 shock waves
Number of subjects: 60
Study 10037363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyelolithotomy
Number of subjects: 60
Study 8560677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg/day)
Number of subjects: 1000
Study 8560677 — intervention group
Group type: COMPARATOR
Intervention: Castration
Number of subjects: 1000
Study 1881993 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 0
Study 7105391 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone diproprionate
Number of subjects: 67
Study 7105391 — intervention group
Group type: COMPARATOR
Intervention: Flunisolide
Number of subjects: 67
Study 7105391 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive cultures pre-trial
Number of subjects: 67
Study 7105391 — intervention group
Group type: COMPARATOR
Intervention: Negative cultures pre-trial
Number of subjects: 67
Study 31707978 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced practice physiotherapists (APP)
Number of subjects: 113
Study 30389760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cell salvage (ICS) reinfusion
Number of subjects: 60
Study 30389760 — intervention group
Group type: COMPARATOR
Intervention: Donor blood transfusion
Number of subjects: 60
Study 26772736 — intervention group
Group type: EXPERIMENTAL
Intervention: Blumgart pancreatic anastomosis
Number of subjects: 253
Study 26772736 — intervention group
Group type: COMPARATOR
Intervention: Cattell-Warren pancreatic anastomosis
Number of subjects: 253
Study 25088807 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (individual and family education, FOBT kits provided)
Number of subjects: 0
Study 25088807 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (individual education only, FOBT kits provided)
Number of subjects: 0
Study 25088807 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (no education, FOBT kits provided)
Number of subjects: 0
Study 25088807 — intervention group
Group type: COMPARATOR
Intervention: Group D (no education or FOBT kits provided)
Number of subjects: 0
Study 22285316 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation 2.4 g/day (1,400 mg eicosapentaenoic acid + 1,000 mg docosahexaenoic acid)
Number of subjects: 31
Study 22285316 — intervention group
Group type: COMPARATOR
Intervention: Placebo (safflower oil)
Number of subjects: 31
Study 20201654 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma disc decompression (PDD)
Number of subjects: 90
Study 20201654 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided transforaminal epidural steroid injection (TFESI)
Number of subjects: 90
Study 17224456 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 85
Study 17224456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 85
Study 17224456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 85
Study 16050885 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP encounter cards rating nine presentation competencies
Number of subjects: 164
Study 16050885 — intervention group
Group type: COMPARATOR
Intervention: Usual feedback
Number of subjects: 164
Study 11952483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocuton S tonometer
Number of subjects: 80
Study 11952483 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 80
Study 11952483 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-tonometry
Number of subjects: 80
Study 9854199 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography followed by endoscopic retrograde cholangiography and sphincterotomy
Number of subjects: 125
Study 9854199 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Number of subjects: 125
Study 9854199 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 125
Study 7876610 — intervention group
Group type: EXPERIMENTAL
Intervention: One, two, or three doses of group A plus group C meningococcal polysaccharide‐CRM197 conjugate vaccine
Number of subjects: 304
Study 7876610 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of conjugate vaccine at 6 months
Number of subjects: 304
Study 7876610 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of conjugate vaccine
Number of subjects: 304
Study 7876610 — intervention group
Group type: COMPARATOR
Intervention: Two doses of meningococcal A plus C polysaccharide vaccine
Number of subjects: 304
Study 2171850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold stimulus applied to the exterior of the left cheek
Number of subjects: 12
Study 2171850 — intervention group
Group type: COMPARATOR
Intervention: Room temperature challenge
Number of subjects: 12
Study 342886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine dekanoate (Dapotum D minor)
Number of subjects: 36
Study 342886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30594892 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-set resistance training (RT) program, 12 weeks, 3 times per week, 10-15 repetitions in 8 exercises
Number of subjects: 48